An open-label phase I multi-center study to determine the recommended dose of the chimeric antigen receptor T-cell treatment CYAD-211 after a non-myeloablative preconditioning chemotherapy in multiple myeloma patients with relapsed or refractory disease | NYU Langone Health

Go Back to All Clinical Trials

An open-label phase I multi-center study to determine the recommended dose of the chimeric antigen receptor T-cell treatment CYAD-211 after a non-myeloablative preconditioning chemotherapy in multiple myeloma patients with relapsed or refractory disease

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

Conditions:
Multiple Myeloma
Age: Between 18 years - 100 years
Gender: Male or Female

Other Inclusion Criteria:

1) Documented diagnosis of Multiple Myeloma (MM) with relapsed or refractory disease to at least two prior MM treatment regimens which should include exposure to immunomodulatory drugs (e.g., lenalidomide, pomalidomide) and proteasome inhibitors (e.g., bortezomib, carfilzomib, ixazomib) either alone or in combination. 2) Presence of measurable disease as per International Myeloma Working Group (IMWG) Response Criteria.

You may not be eligible for this study if the following are true:

1) History or presence of clinically relevant central nervous system (CNS) pathology. 2) Patients with an autologous stem cell transplant within 12 weeks of registration or an allogeneic stem cell transplant within 6 months of starting study treatment.